|
|
TTD Drug ID:
DAP000006
Drug
Information |
Name | Sorafenib | Synonyms | BAY-54-9085; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; BAY-43-0006; Sorafenib [INN]; NCGC00167488-01; CID216239; D08524; CHEBI:50924; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Kinome_766; Bio-0100; sorafenibum; BAY 439006; Sorafenib; AC-1674; BAY 54-9085 (tosylate salt); LS-187788; DB00398; ZINC01493878; 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-; LS-186067; MolPort-003-850-270; Nexavar; DB07438; BAY-43-9006; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; NSC-724772; K00597a; AB1004622; BRD-K23984367-001-01-8; STK627350; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; I06-0856; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; BAY 43-9006 (free base); CHEBI:47228; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; nchembio.117-comp17; CHEMBL1336; N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; BAX; EN002709; AC1L50CF; Sorafenib (INN); 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-; NSC747971; LS-187021; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; UNII-9ZOQ3TZI87; BAY 43-9006; BAY43-9006; 284461-73-0; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide | Trade Name | Nexavar | Company | Bayer AG/Onyx Pharmaceuticals | Indication | Advanced renal cell carcinoma [ICD9: 189 ICD10: C64] | Launched [1] | Hepatocellular carcinoma, NSCLC, melanoma [ICD9: 155, 162, 172 ICD10: C22.0, C33, C34, C43] | Phase III [1] | Myelodyspalstic syndrome, AML, head & neck cancer, breast, colon, ovarian, pancreatic cancer [ICD9: 140-149, 140-229, 157, 183, 205.0 ICD10: C00-C96, C07-C14, C25, C32, C33, C56, C92.0] | Phase II [1] | Structure |
Click to save drug structure in 3D MOL format
Click to save drug structure in 2D MOL format
| InChI | 1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6 -14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,2 6,30)(H2,28,29,31) | InChIKey | MLDQJTXFUGDVEO-UHFFFAOYSA-N | Canonical SMILES | CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F | Therapeutic Class | Antineoplastic Agents | CAS Number | CAS 284461-73-0 | Formula | C21H16ClF3N4O3 | PubChem Compound ID | CID 216239. | PubChem Substance ID | SID 789424. | ChEBI | 50924; | SuperDrug ATC ID | L01XE05 | L01XE05 | Target | B-Raf proto-oncogene serine/threonine-protein kinase |  | Inhibitor | [2][3][4] | B-Raf proto-oncogene serine/threonine-protein kinase |  | Multitarget | [2][3][4] | Proto-oncogene tyrosine-protein kinase receptor ret |  | Inhibitor | [2][3][4] | Proto-oncogene tyrosine-protein kinase receptor ret |  | Multitarget | [2][3][4] | Vascular endothelial growth factor receptor |  | Inhibitor | [2][3][4] | Vascular endothelial growth factor receptor |  | Multitarget | [2][3][4] | Ref 1 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. To Reference | Ref 2 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference | Ref 3 | Pituitary tumors. Curr Treat Options Neurol. 2009 Jul;11(4):287-96. To Reference | Ref 4 | Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. Epub 2006 Nov 28. To Reference |
Welcome
to sign our Guestbook.
If you
find any error in data or bug in web service, please kindly report it
to Dr.
Zhu.
Dr.
Chen Yuzong
Deputy Director of Center
for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore
All rights reserved.
|